chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever of 101.9 F for over 72 hours. Headache, body ache, painful skin over whole body, injection site swelling to 9 inches with redness and heat, fatigue (continues until today). Began to resolve on day four after immunization. /after four weeks still have a small, hard bump where vaccine was injected.  Alternated ibuprofen and acetaminophen around the clock to bring fever down and relieve aches.
This spontaneous report was received from a medical assistant referring to an unspecified number of patient of unspecified gender and age. Since 05-FEB-2017, the unspecified number of improperly stored doses of the VAQTA (lot number M016191, expiration date 26-MAY-2017, lot number M011116, expiration date 01-JUN-2017) (formulation, dose, frequency, route of administration and indication were not reported) were administered to the patients. From 05-FEB-2017 to 01-MAR-2017, the doses were stored 10 times in temperature colder than 32F (28.3F) for an unspecified period of time. It was also reported that the first excursion colder that 32F occurred on 15-FEB-2017. Data logger was involved. There was no previous excursion reported. No adverse effects have been reported. Additional information has been requested.; Sender's Comments: US-009507513-1703USA007375: US-009507513-1703USA007373: US-009507513-1703USA007374: US-009507513-1703USA007371: US-009507513-1703USA007372:
Still feels bad 3 weeks post-vaccine-achy, difficulty walking more than 60 feet due to weakness/pain  in heart, headache 5-6 times per day, pain in left hand and neck  Started with tachycardia 4 days post vaccine.  Metallic taste 6 days post vaccine, facial allergy 8 days post vaccine, painful swelling in left leg 11-12 days post vaccine
weakness Narrative: Patient received influenza vaccine in his home. The following day, caregiver called to report patient woke up very weak, hypotensive, and with new diarrhea. No fever, nausea, vomiting, or other symptoms reported. Of note, patient also had home hospice consulted pending due to patient not fully recovering from PNA and recent CVA with continued decline in overall health.
Jannsen vaccine was administered outside of Facility- reported by patient ? NO LOT NUMBER WERE SUPPLIED ------------------------------------------------------------------------------------------------------------------------------- I63.89 SUPERIOR CEREBELLAR ARTERY SYNDROME 4/12/2023 HYPERTENSIVE EMERGENCY I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 3/25/2023 HYPERTENSIVE EMERGENCY
High fever states unable to check because pt was continually shaking & uncontrollable; had shakes & irritability until 26FEB92; didn't walk until 21-22 hrs p/inject;
Itchy rash; A spontaneous report (United States) was received from a Consumer concerning a 79-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events itchy rash.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 20 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: Unknown) intramuscularly for prophylaxis of COVID-19 infection.  On 27 Jan 2021, the patient experienced the event(s) itchy rash.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), itchy rash was unknown..
two skin procedures performed in his surgeons office the day before- one on his nose and one on his arm; nose was still slightly bleeding; This is a spontaneous report from a contactable consumer(patient).  A 72-year-old male patient received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 30Dec2020 at single dose for COVID-19 immunization. Medical history included phlebotomy in Sep2020 because his blood was "too thick" and he had no history of a clotting problem until the time of the report. The patient's concomitant medications were not reported. He reported having two skin procedures performed in his surgeons office the day before- one on his nose and one on his arm. The surgeon nicked a vein on his arm and it began bleeding again last night. The arm was addressed in the emergency deportment(ED) and was fine at time of the report. His nose was still slightly bleeding. This morning his blood was drawn for a CT scan and it took a little while to get the bleeding to stop. He had a "phlebotomy" in Sep2020 because his blood was "too thick" and he had no history of a clotting problem until the time of the report. The patient asked if the Covid vaccine act as an anticoagulant. He had not spoken to this HCP yet. He was not on a blood thinner. The reporter considered that the event was non-serious. The outcome of the event arm bleeding/bleeding was recovered, of event "nose was still slightly bleeding" was not recovered.    Information about lot/batch number has been requested.
pt woke up with an extreme severe headache and nausea.  Vision was blurred, he had joint point, body aches and pains.  He used ice pack for headache.  These symptoms lasted about 24 hours. On 5/13/21 Pt still has blurry vision but other symptoms have subsided.
Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion); Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion)) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients administered Moderna vaccine while temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.  There had been no power outages that would have impacted the Moderna vaccine. However, the Healthcare professional reiterates that because the facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. Were filling out a temperature excursion assessment with the State at the time of report. It was reported that no adverse reactions were reported by any patients.  No treatment medication was provided.
I do not recall the exact symptoms since it was almost a year ago. It was all recorded on my check in. But I do know since I had the COVID-19 shot I have had joint pains & chest pains.
Woke up 1 week after my vaccination and my left arm was hot, itchy and swollen at injection site. My shoulder area was very red and raised.   As the day progressed it got very uncomfortable.  Called doctor and they advised me to put ice on it.  The next day I applied ice several times and took an Allegra to get some relief from the pain in my shoulder and arm.  Symptoms started improving after 48 hours.  Redness continued for 4 days,
On 11/2/04 I received my second pneumococcal vaccination. I had received this vaccination 9 years prior with no reaction. My physician felt it necessary that I receive the vaccination related to my asthma. I take a steroid preparation inhaler BID for my asthma and I am 56 years old and work in a nursing home. Within 24 hours my left deltoid area and the entire upper arm was so grossly edematous, that it was difficult to put my arm in my scrub top. My arm was red, hot, and extremely painful. I applied ice frequently, took Motrin and Tylenol for 24 hours. I did have some wheezing and was able to resolve that with my nebulization treatment. I took Benadryl ever 4 hours. On 11/04/04, I went to my private physician since the reaction was still evident and I was becoming very concerned. My physician agreed that this was a very bad reaction, and stated that there are two schools of thought, and he does not recommend the second shot until after 65 years of age. However, he felt it would improve and encouraged me to keep caring for my arm as I had been doing. On Saturday, 11/6/04, the edema/swelling had subsided. Once the swelling was gone, I have had constant radiating pain from the deltoid down into my fingers and thumb, and up into my neck on rotation of my head which has not gone away. It is a burning pain, agonizing in nature. It is so painful it stops me from working. I have been taking Tylenol and Motrin and will return to my physician if this does not subside. I contacted the supplier of our vaccines and was told to inform you of this information. I have the vial of serum that was used. This vial had just been opened. Another nurse also received an injection from this vial, and also had a reaction (this was his second injection). One administrative employee also had an injection from this vial with no reaction (this was her first pneumonia injection). I will encourage the other nurse to write to you and describe his reactions if you feel this is necessary. The company was called by the pharmacy, and they replied that they do not recommend a second dose. This seems to be left up to the individual physicians whether they recommend the second dose or not.
Her arm was hard, had red circle and was real hot; Upset; Her arm was hard at the injection site; Her arm was hard, had red circle and was real hot; Injection site close to elbow; This is a spontaneous case reported by consumer via Agency (reference number: SEQ19-05563) and initially received on 24-Oct-2019, concerning a 46-year-old, female patient.  The patient had no relevant medical history her concomitant medications included stomach pill', as reported, for unknown indication.   On 22-Oct-2019, the patient was administered Flucelvax QIV [Influenza vaccine, subunit influenza vaccine polyvalent, dose: 0.5ml, route of administration, anatomical location, batch number and expiry date: not reported] for influenza prophylaxis.  On 24-Oct-2019, 2 days after vaccination, the patient went to scratch her arm and noticed a hard area at the injection site, that was close to her elbow, and red circle and the injection site was real hot (explicitly coded as 'Vaccine administered at inappropriate site').  Patient received no treatment for these events. On the same day, the pharmacist reported that the consumer was upset and hasn't come in to let her check the reaction site and location of injection. The pharmacist also noted that she always gives vaccines intramuscular in the deltoid.  The outcome of all the events was not recovered, at the time of this report.  The reporter assessed the case as non-serious and did not provide causality.  Company comment: The patient developed vaccination site warmth, emotional distress, vaccination site induration and vaccination site erythema two days after vaccination with the suspect product, Flucelvax QIV. Chronology is plausible. Reportedly, injection site was close to elbow (explicitly coded as 'Vaccine administered at inappropriate site').  Causality for the event of product administered at inappropriate site is assessed as not related, while for all other events as possibly related.; Sender's Comments: The patient developed vaccination site warmth, emotional distress, vaccination site induration and vaccination site erythema two days after vaccination with the suspect product, Flucelvax QIV. Chronology is plausible. Reportedly, injection site was close to elbow (explicitly coded as 'Vaccine administered at inappropriate site').  Causality for the event of product administered at inappropriate site is assessed as not related, while for all other events as possibly related.
This spontaneous report as received from a registered nurse. On an unknown date the nurse reported that improperly stored GARDASIL (lot # J009243) .5 ml, were administered to two unspecified patients intramuscularly. No adverse events were reported. Additional information has been requested.
Patient called on 12/16/16 to report that her arm is red, swollen and warm all the way from her elbow to the injection site. Also there is redness on the opposite of her injection site on the same arm. Patient was advised to use ibuprofen and warm or cool compresses.
Swelling at injection site, hot and red injection site lasting 5 days, infection at site treated with antiobiotics, diarrhea lasting for 5 days.
This spontaneous report as received from a medical assistant refers to a 16 week old male patient. On approximately 04-APR-2013 the patient was vaccinated with the first dose of ROTATEQ (lot# unspecified) at age 16 weeks. The outcome of the event was unknown. Additional information has been requested.
her arm was so sore, it is hurting; This is a spontaneous report from a contactable consumer (Patient herself). A 64-year-old female patient received second dose of BNT162b2 (BNT162B2) via an unspecified route of administration on 12Apr2021 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation.The patient medical history and concomitant medications were not reported. Previously the patient received first dose of BNT162b2 (BNT162B2) via an unspecified route of administration on 22Mar2021 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. she did not feel anything nor had side effects after first dose. The patient experienced her arm was so sore, it is hurting on 13Apr2021. She did experience that "her arm was so sore, it is hurting, she took Tylenol, and she wanted to know if it would hurt having a heating pad on her arm for the pain. Therapeutic measures were taken as a result of the event. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
muscle aches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 02Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MYALGIA (non-serious), outcome "unknown", described as "muscle aches".  Additional information: Patient has scheduled cosmetic buttocks tomorrow 04Mar2021 and she wanted to know if it's ok.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Nov-2021 at 1:20 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 03-Nov-2021 at 1:20 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant drugs were not reported.  The vial undergone temperature excursions for 1 month. The vial was in frozen state at the time of the excursion (Vials in question stored in a super cold Freezer) and minimum reached temperatures was negative 82 degrees Fahrenheit. The patient was given dose from vial that was stored in an ultracold freezer which was colder than it should have been. The vial was moved from freezer to refrigerator on 19-Nov-2021, when the Moderna Covid-19 vials went from the super cold freezer to the refrigerator. The vials were returned to the freezer/refrigerator or maintained at room temperature.  The reporter stated that total 70 vials were still in the ultra-cold freezer and 8 vials were in the refrigerator. No vaccine state changes were noticed. The vaccine was never refrozen. None of the vials were punctured. No previous temperature excursions were reported. Total 280 patients received Moderna Covid 19 stored at minus 82 degrees Fahrenheit.  Treatment details were not given.   This case was linked to MOD-2021-402935 (Patient Link).
Patient has to see an Ear, Nose, and Throat specialist because as of 3 days after the vaccine, they experience extreme vertigo when they stand up. Had a falling episode in their bathtub.
I had some medical condition but I after taking Pfizer vaccine in March and April, my all medical conditions seems going away; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection), dose 1 via an unspecified route of administration on Mar2021 (Batch/Lot number was not reported) as dose 1, single and dose 2 via an unspecified route of administration on Apr2021 (Batch/Lot number was not reported) as dose 2, single, for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date in 2021, the patient reported that "I had some medical condition but I after taking Pfizer vaccine in Mar and Apr, my all medical conditions seems going away. This is something positive effect happen after taking Pfizer vaccine. I am just writing this message in case someone can benefit of it". The outcome of event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
approx 2hr p/vax lt arm swelling, tenderness, hives on upper body, neck, face, DPH given 11AM w/relief of sx;
Patient has a bruise at the injection site and a warm, red, swollen patch on her left arm slightly below the injection site. No fever or pain. The patient was instructed to ice the area and contact her physician if the swollen area increases or her symptoms worsen.
The patient received the vaccine at about 2:40PM.  She was in the store until 3PM and she didn't have any symptoms and left the pharmacy.  She returned at about 3:38PM with swelling and redness of her cheeks and she had an itchy throat she said.  She was breathing fine.  I advised her to take some liquid Benadryl and she took 25mg.  She said in our waiting room until 3:54PM at which time she said she was doing better and wanted to leave.  I advised her to be evaluated at an urgent care.  I called to check on her at 5:35PM and she said she had taken another 25mg of Benadryl at home and was feeling better.  She said the redness and swelling on her cheeks was going down.
Headache fatigue, chills Narrative:  employee states: around 10am the next day experienced intense headache. Around 11 am was feeling weak/tired. by noon started feeling chills. went home slept one day next day was fine. did not self medicate
Patient described arm being more painful then his boostrix vaccine he received in the left arm within a few hours. He woke up the next day with swelling and rash down his arm. He was treated for cellulitis on 11/15/2020.
This is a spontaneous report from a contactable pharmacist. A patient of unspecified age and gender received the second dose of TRUMENBA at single dose on an unknown date. Concomitant medications and medical history were not reported. The patient had a local reaction, also had like fever and like body ache on an unknown date. The pharmacist believed that these reactions were related to TRUMENBA as those were injection site reactions, and they were on the area around that injected. Outcome was not reported. Follow-up (02OCT2015): Follow-up attempts are completed.  No further information is expected.
hep B, adolesent or pediatric 12-FEB-2003/hep B, adolesent or pediatric 22-APR-2004; hep B, adolesent or pediatric 17-NOV-2002/hep B, adolesent or pediatric 12-FEB-2003; This spontaneous report has been received from a physician, via medical records and immunization record from a case in litigation for hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (# 2211USA009542), concerning a 13-week-old, female patient. The patient's medical history, concurrent conditions and concomitant therapies prior to vaccinations were not reported.  On 17-NOV-2002, the patient was vaccinated with hepatitis b vaccine (recombinant) (manufacturer unknown) adolescent or pediatric, administered intramuscularly(IM) (exact dose, lot #, expiration date, site of administration were not provided). On 12-FEB-2003 (inappropriate schedule of product administration), the patient was vaccinated with hepatitis b vaccine (recombinant) (manufacturer unknown) adolescent or pediatric, administered IM (exact dose, lot #, expiration date, site of administration were not provided). On 22-APR-2004 (inappropriate schedule of product administration), the patient was vaccinated with hepatitis b vaccine (recombinant) (manufacturer unknown) adolescent or pediatric, administered IM (exact dose, lot #, expiration date, site of administration were not provided). According to immunization record, on 12-FEB-2003 and 22-APR-2004, the patient was vaccinated with diphtheria vaccine toxoid (+) hepatitis b vaccine rhbsag (yeast) (+) pertussis vaccine acellular 3-component (+) polio vaccine inact 3v (vero) (+) tetanus vaccine toxoid (PEDIARIX) (discrepant information).   This is one of two reports regarding the same patient.  All available medical records will be provided upon request.; Sender's Comments:  US-009507513-2211USA009542: